Home/Ingredients/Adaptogens/Bacopa (generic powder)
⚑ Unstandardised — caution FSSAI Permitted India availability: Very high Evidence: Limited

Bacopa monnieri
(generic powder)

Generic Brahmi powder — sold by the kilogram across India, with two compounding problems: unverified bacoside content typically far below clinical trial doses, and a naming confusion so severe that many products labelled Brahmi do not contain Bacopa monnieri at all. The 12 RCTs everyone cites for Brahmi were not run on this material.

Updated: May 2026~13 min read14 citations
N
Naked Compound Research TeamReviewed by the full team · Authors page →
<2%
Typical bacoside content in generic Brahmi leaf powder vs 20–55% in standardised extracts used in clinical trials.
0
Rigorous RCTs conducted on unstandardised Brahmi powder at supplement doses. All cognitive evidence applies to standardised extracts only.
2 plants
Brahmi in India refers to both Bacopa monnieri and Centella asiatica. Many Brahmi products contain the wrong plant for cognitive applications.
Rs.50–200
Per month for generic Brahmi powder vs Rs.200–500 for standardised extract. The Rs.150 saving does not justify the evidence gap.
On this page

What is generic Brahmi powder?

Generic Brahmi powder is dried and ground Bacopa monnieri whole plant or leaf material — harvested, dried, and powdered without extraction, concentration, or bacoside standardisation. It has been documented in classical Ayurvedic texts including the Charaka Samhita and Ashtanga Hridayam as a medhya rasayana — a class of herbs indicated for cognitive enhancement and memory. [1]

In the modern Indian supplement market, this material is sold in 500mg capsules, 100g powder bags, and multi-herb Brahmi tablets — often at ₹50–200 per month. The problem is systematic: these products cite clinical trials that were conducted on high-concentration standardised extracts (CDRI-08 at 20% bacosides, Bacognize at 45% bacosides), not on the generic leaf powder they contain. [2]

The Brahmi naming problem — two plants, one name

"Brahmi" in India is used interchangeably — and incorrectly — for two distinct plants with different bioactive profiles. [3]

Bacopa monnieri (Brahmi / Jalabrahmi): A small creeping wetland herb with bioactives bacosides A and B. This is the plant with 12 RCTs on cognitive function. Found in Tamil Nadu, Andhra Pradesh, and West Bengal.

Centella asiatica (Brahmi / Mandukparni / Gotu kola): A different herb with bioactives asiaticoside, madecassoside, and asiatic acid. Called "Brahmi" in northern India. Different mechanisms, different evidence base, not interchangeable with Bacopa. [5]

A product substituting Centella asiatica for Bacopa monnieri while citing Bacopa cognitive trial data is providing false evidence claims. Always verify the scientific name on any Brahmi product. [6]

⚠

How to verify you have the right Brahmi

Always check for the full scientific name: Bacopa monnieri — not Centella asiatica, not just "Brahmi." If only "Brahmi" appears without the Latin name, you cannot know which plant you are getting. This labelling gap is a regulatory failure FSSAI should address. [6]

The bacoside content problem

Even when a generic Brahmi product correctly contains Bacopa monnieri, the bacoside content is unpredictable and typically far below clinical trial levels. Published analyses find total bacoside content ranging from 0.5% to 2.2% in dried leaf powder — compared to 20% in CDRI-08 and 45% in Bacognize. [7]

At 500mg generic Brahmi powder: approximately 2.5–11mg bacosides. At 300mg CDRI-08 (20% bacosides): 60mg bacosides. At 300mg Bacognize (45%): 135mg bacosides. The clinical trials used extracts delivering 60–135mg bacosides per day — at least 6–54× more than generic powder capsules deliver. [8]

BACOSIDE DELIVERY — per day at label dose Generic powder (500 mg) ~5–11 mg bacosides ✗ below clinical threshold CDRI-08 (300 mg extract) 60 mg ✓ Bacognize (300 mg extract) 135 mg ✓ clinical trial range Generic capsule doses deliver 6–54× fewer bacosides than all published clinical trials used
Fig. 1 — Bacoside delivery comparison at label doses. Generic Brahmi powder at 500mg delivers far below the clinical evidence threshold regardless of how many capsules are taken.

Evidence audit

Study / Evidence typeForm usedApplies to generic powder?Key findingGrade
Stough et al. (2001); Roodenrys et al. (2002); Kongkeaw meta-analysis (2014) CDRI-08 extract ✗ No All significant cognitive RCTs used 20–55% standardised extract at 60–135mg bacosides/day. Not applicable to generic powder at supplement capsule doses. A
Charaka Samhita — classical use texts Whole plant churna / ghrita ✓ Yes Traditional medhya rasayana use at 3–10g plant material/day in ghrita or taila. Historical use legitimate in Ayurvedic context. Not equivalent to supplement capsule evidence. C
In vitro / animal bacoside pharmacology Isolated bacoside A compounds ~ Mechanistic only Bacosides demonstrate AChE inhibition in vitro. Present in generic powder at subclinical concentrations. Cannot extrapolate to clinical cognitive effect at supplement doses. C

Dosage reality

The classical Ayurvedic dose is 3–10g of dried plant per day in Brahmi ghrita or Brahmi taila preparations. At 5g generic powder with ~1% bacosides, you deliver approximately 50mg bacosides — approaching clinical trial range. The modern supplement capsule dose (500mg–1.5g/day) delivers 5–15mg bacosides — well below threshold. The maths do not support clinical claims at capsule doses. [10]

ified)
RCTs on this form0
Best useAyurvedic churna / ghrita
India price/month₹50–₹200
Bacoside/day (capsule)5–15 mg
Evidence-backed choice
CDRI-08 extract
Bacosides≥20% (HPLC verified)
RCTs on this form10+
Best useAll clinical endpoints
India price/month₹200–₹500
Bacoside/day60 mg
Highest standardisation
Bacognize extract
Bacosides≥45% (HPLC verified)
RCTs on this form4+
Best useAll clinical endpoints
India price/month₹300–₹700
Bacoside/day135 mg

India-specific context

🇮🇳 India market data

A plant native to India, systematically misrepresented in the supplement market

₹50–₹200
Per month for generic Brahmi powder — the cheapest nootropic on Indian shelves. Evidence-per-rupee is the problem, not the price itself.
2 plants
Both called "Brahmi" in India — Bacopa monnieri and Centella asiatica. FSSAI does not mandate scientific name clarity on supplement labels, enabling widespread consumer confusion.
FSSAI ✓
Bacopa monnieri permitted under Schedule II. However, the regulation does not require extract standardisation or bacoside content verification — the core quality gap.

Bacopa monnieri is native to India and cultivated in Tamil Nadu, Andhra Pradesh, West Bengal, and Uttar Pradesh. It is one of the cheapest medicinal plants in the world — raw dried leaf costs ₹50–200/kg at wholesale. This low cost is why generic powder is profitable at very low retail prices, and why the ₹150–200 difference in monthly cost between generic powder and standardised extract represents a significant business incentive to keep selling the generic form. [11]

The FSSAI labelling gap is significant: under current regulations, a product can legally list "Brahmi" without specifying Bacopa monnieri vs Centella asiatica, and without stating bacoside content or extraction methodology. A brand can legally reference CDRI-08 clinical trial data in marketing materials while selling generic leaf powder. Until FSSAI mandates botanical name clarity and minimum extract standardisation for cognitive claims, this situation will continue. [12]

Lab test data

Published phytochemical analysis
Bacopa monnieri leaf — bacoside content
0.5–2.2% bacosides (range across studies)
Mean bacoside content (dried leaf)~1.2%
Variability factor (season, location)4–5×
Bacoside at 500mg powder2.5–11 mg
Significant natural variability in bacoside content depending on ecotype, harvest season, plant part ratio, and processing conditions. No supplement brand publishes batch-specific bacoside data for generic powder products. [7]
Species adulteration data — India
Centella vs Bacopa authentication
Adulteration documented in literature
Products with wrong species (est.)Not systematically studied
DNA barcoding studies — adulteration rate15–30% (reported)
NABL botanical authentication COAEssentially none on market
DNA barcoding studies of Ayurvedic herbal products find species adulteration in 15–30% of samples tested. Centella/Bacopa confusion is among the most commonly reported. [13]
Heavy metals — wetland cultivation risk
Bacopa monnieri — soil contamination
Risk present — unmonitored in most products
Lead risk (wetland soil)Documented in literature
Cadmium accumulationBacopa is a hyperaccumulator
Products with heavy metal COAVery few generic brands
Bacopa monnieri is a known hyperaccumulator of cadmium and lead from wetland soils. This is a meaningful safety concern for generic powder sourced from industrially contaminated waterways. Standardised extracts (CDRI-08 / Bacognize) include heavy metal screening — generic powder products typically do not. [14]

Indian brand comparison

Brand & product₹/monthFormSpecies verified?Our take
Patanjali Brahmi Churna₹50–₹100Dried leaf powder churnaLikely Bacopa monnieri (Patanjali specifies)Traditional churna format — appropriate for Ayurvedic use at 3–6g in warm milk or ghee. Not appropriate as a substitute for standardised extract at capsule doses.
Himalaya Brahmi tablet (generic form)₹120–₹200Dry root/plant extract — standardisation unclearBacopa monnieri — species specifiedHimalaya specifies the correct species but does not clearly state bacoside percentage or extraction method. A step up from anonymous generic powder but insufficient for clinical-protocol use.
Organic India Brahmi capsules₹150–₹250Certified organic leaf powderBacopa monnieri specifiedOrganic certification addresses pesticide concern. Does not address bacoside standardisation. Appropriate for traditional use; not for clinical nootropic application.
Generic Amazon "Brahmi" capsules₹80–₹200Unknown species + extractionSpecies not specified on many productsHighest risk category — species may be Centella asiatica, bacoside content unverified, no heavy metal data. Avoid entirely for supplement use.
Kerala Ayurveda / Kottakkal Brahmi products₹150–₹400Traditional preparations (ghrita, taila)Classical Ayurvedic preparations — species authenticatedAuthentic classical Ayurvedic preparations from licensed manufacturers. Appropriate for Ayurvedic therapeutic use under a vaidya's guidance. Not a modern supplement form.

Related conditions

Traditional use

Ayurvedic medhya rasayana therapy

Classical Brahmi ghrita (Bacopa in ghee) and Brahmi taila (Bacopa in sesame oil) are documented preparations in the Ashtanga Hridayam and other classical texts. These preparations are used at 3–10g equivalent Bacopa/day with lipid carriers that may improve bacoside absorption. Traditional Ayurvedic use under a qualified vaidya is a legitimate application for generic Brahmi. The issue is exclusively with modern supplement capsules at sub-clinical doses claiming clinical evidence. [1]

Cognitive

Memory and learning — use standardised extract instead

All clinical evidence for Bacopa's cognitive effects is from CDRI-08 or Bacognize standardised extracts at 60–135mg bacosides/day. Generic powder at typical supplement doses delivers 5–15mg bacosides — well below the evidence threshold. For memory, learning, and processing speed applications, switch to standardised extract. The extra ₹150–300/month is justified by the entire clinical evidence base. See our CDRI-08 / Bacognize page. [8]

Hair and scalp

Brahmi oil for hair — legitimate traditional use

Brahmi taila (Bacopa-infused sesame or coconut oil) applied topically to the scalp is a traditional preparation with a distinct and valid use case from the oral supplement. Topical bacoside absorption bypasses the oral bioavailability limitations. This is a traditional preparation where generic Bacopa leaf powder steeped in oil is the appropriate and authentic form — not a context where standardised extract is required.

Paediatric

Children's memory — Ayurvedic context

Classical Ayurvedic practice of giving Brahmi to school-age children (as churna in milk or as Brahmi ghrita) is historically grounded and supported by the CDRI-08 trial in Indian children (Dave et al. 2014). However: the Dave trial used standardised CDRI-08 extract, not generic powder. For children's cognitive support in a modern supplement context, use standardised extract at age-appropriate doses (150–225mg CDRI-08/day) rather than generic powder. [9]

Commonly taken together

Ghee (as traditional anupana)

Traditional synergy

The classical Ayurvedic preparation pairs Brahmi with ghee (clarified butter) as the anupana (carrier vehicle). Bacosides are lipophilic — fat-soluble ghee improves their absorption from the GI tract. At traditional doses (3–6g Brahmi churna in 1–2 teaspoons ghee with warm milk), this may partially bridge the bacoside delivery gap between generic powder and standardised extract. Still below standardised extract bacoside delivery, but the most evidence-aligned approach within the generic powder context. [1]

Shankhapushpi (Convolvulus pluricaulis)

Traditional combination

Classical Ayurvedic medhya rasayana formulations often combine Brahmi with Shankhapushpi — another medhya herb with mild cholinergic and GABA-ergic properties. This pairing appears in Brahmi Ghrita formulations and Saraswatarishta (a classical medicated wine). The traditional combination is coherent — both act on cognitive and stress pathways via complementary mechanisms.

Upgrade to standardised extract

Best action

If you are taking generic Brahmi powder for cognitive outcomes — memory, learning rate, processing speed — the most impactful step is to replace it with a CDRI-08 or Bacognize standardised extract. Neuherbs Brahmi Extract (20% bacosides, ₹280–400/month) and OZiva Brahmi (₹350–500/month) are the best domestic Indian options. The price difference is ₹100–300/month; the evidence gap is 12 RCTs vs 0. See our standardised Bacopa page.

Ashwagandha KSM-66

Traditional pairing — use both standardised forms

Brahmi (Bacopa) and Ashwagandha are the two most commonly combined medhya rasayana herbs in classical Ayurvedic formulation. The combination addresses cognitive enhancement (Bacopa) and stress resilience (Ashwagandha) simultaneously — a complementary pairing. However: for this pairing to deliver clinical benefit, both should be in standardised extract form (CDRI-08 / KSM-66), not generic powders. Generic powder + KSM-66 is better than two generic powders, but standardised both for maximum benefit.

Scoring rubric — full breakdown

1. Evidence quality

2.0/10

Zero double-blind RCTs conducted on generic Brahmi powder at supplement capsule doses. All cognitive evidence applies to standardised extracts. Traditional use and in vitro mechanistic data exist but cannot substitute for clinical trial evidence when specific cognitive outcomes are being marketed. Score 2.0 — identical to our generic ashwagandha powder score — because the same evidence attribution problem applies: the trials were not run on this material. [2]

2. Dosage confidence

2.0/10

Two compounding problems: (a) bacoside content variability in generic powder (0.5–2.2%) makes bacoside dose impossible to calculate from capsule weight alone; (b) species adulteration risk means you cannot be confident even the correct plant is present. Traditional Ayurvedic dosing guidance (3–10g/day of whole plant) is well-characterised but is not the context in which these products are sold. For modern supplement capsule use, dosage confidence is essentially zero. [10]

3. India market fit

6.5/10

Bacopa monnieri is native to India, extremely cheap, culturally embedded in Ayurvedic tradition, and widely available. For traditional Ayurvedic use at classical preparations and doses — it is the appropriate form. The market fit score of 6.5 reflects this legitimate traditional use context, penalised for: (a) systematic misrepresentation of its evidence base in modern supplement marketing; (b) the Brahmi/Centella naming confusion; (c) the heavy metal hyperaccumulation risk from unverified cultivation sources.

4. Safety profile

6.5/10

At traditional doses in correct preparations, generic Brahmi has a long history of safe use. At modern supplement capsule doses (500mg–1g/day), adverse event data is limited but the low bacoside delivery means pharmacological effects — both beneficial and adverse — are attenuated. The primary safety concerns specific to generic powder are: (a) cadmium and lead hyperaccumulation from contaminated wetland soils; (b) GI intolerance when taken on empty stomach (shared with standardised extract); (c) species adulteration risk — Centella asiatica has its own pharmacology and drug interactions distinct from Bacopa. We score lower than standardised extract (7.5) primarily due to the heavy metal contamination risk and species uncertainty. [14]

5. Label accuracy (tested products)

2.0/10

The worst-scoring dimension. Three compounding problems: (a) most products do not specify the botanical species — "Brahmi" on a label does not tell you which plant is present; (b) no bacoside content or standardisation data is published by any major Indian generic Brahmi supplement brand; (c) heavy metal testing is almost universally absent from publicly available product documentation. The combination of species uncertainty, bacoside uncertainty, and contamination risk without any COA transparency makes this the worst-scoring label category we have reviewed for any Indian supplement ingredient. [13]

References

  1. 1
    Charaka Samhita, Chikitsa Sthana 1.3 (Medhya rasayana chapter). Referenced in: Chunekar KC, Pandey GS. Bhavprakash Nighantu. Varanasi: Chaukhambha Bharati Academy; 2010. ISBN:8170074916.
  2. 2
    Pase MP, et al. The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials. J Altern Complement Med. 2012;18(7):647–52.doi:10.1089/acm.2011.0367
  3. 3
    Bhanumathy M, et al. Brahmi — a memory booster (Bacopa monnieri Linn.). Pharm Innov J. 2016;5(7):42–5. Open access.
  4. 4
    Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res. 2013;16(4):313–26.doi:10.1089/rej.2013.1431
  5. 5
    Gohil KJ, et al. Pharmacological review on Centella asiatica: a potential herbal cure-all. Indian J Pharm Sci. 2010;72(5):546–56.doi:10.4103/0250-474X.78519
  6. 6
    Food Safety and Standards Authority of India. Health Supplements, Nutraceuticals, Food for Special Dietary Use Regulations, 2022. Schedule II — labelling requirements for herbal ingredients.FSSAI Official Gazette
  7. 7
    Srivastava P, et al. Phytochemical and pharmacognostical study of Bacopa monnieri. Asian J Pharm Clin Res. 2012;5(2):65–8. Open access.
  8. 8
    Kongkeaw C, et al. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014;151(1):528–35.doi:10.1016/j.jep.2013.12.044
  9. 9
    Dave UP, et al. An open-label study to elucidate the effects of standardized Bacopa monnieri extract in the management of symptoms of attention deficit hyperactivity disorder in children. Adv Mind Body Med. 2014;28(2):10–5. PMID:24682000.
  10. 10
    Russo A, Borrelli F. Bacopa monniera, a reputed nootropic plant: an overview. Phytomedicine. 2005;12(4):305–17.doi:10.1016/j.phymed.2003.12.008
  11. 11
    Rauf K, et al. Bacopa monnieri (L.) Pennell — a review of its traditional uses, phytochemistry, and pharmacology. Biomed Pharmacother. 2021;138:111528.doi:10.1016/j.biopha.2021.111528
  12. 12
    FSSAI. Health Supplement Regulations 2022. Op. cit. [6]
  13. 13
    Newmaster SG, et al. DNA barcoding detects contamination and substitution in North American herbal products. BMC Med. 2013;11:222.doi:10.1186/1741-7015-11-222
  14. 14
    Mishra S, Bhatti R. Phytoremediation potential of Bacopa monnieri for cadmium removal from water. Int J Phytoremediation. 2010;12(5):530–40.doi:10.1080/15226510903353249

Affiliate disclosure. Naked Compound participates in the Amazon Associates India affiliate programme. Some product links earn a small commission at no additional cost to you. Commission does not influence our scores, rankings, or conclusions. Full policy: conflicts-policy